Savient Pharmaceuticals presents four abstracts on Puricase at rheumatology conference

By Elaine Rigoli

Tampa, Fla., April 19 - Savient Pharmaceuticals, Inc. announced Wednesday that four abstracts further detailing data on the phase 2 clinical trial results of its drug development candidate, Puricase (PEG-uricase), will be presented at the European League Against Rheumatism 2006 Annual Congress in Amsterdam, the Netherlands, being held June 21 to June 24.

In phase 2, Puricase achieved a rapid and continuous control of plasma uric acid and also showed beneficial clinical outcomes, such as reduction in frequency of gout flares and elimination of gout tophi, officials said.

"Since the announcement of our positive phase 2 results, Puricase has garnered significant scientific and medical attention. We believe the ability of Puricase to normalize plasma uric acid levels within hours and eradicate gout tophi with 3 months of treatment is indeed unprecedented. We are extremely pleased at the acceptance of these abstracts on Puricase at this prestigious scientific meeting for the European rheumatology community and look forward to advancing Puricase into phase 3 and towards commercialization," president and chief executive officer Christopher Clement said in a news release.

The company said it is also reporting results of a 12-month non-interventional (observational) study in the orphan gout population.

Based in East Brunswick, N.J., Savient is an emerging specialty pharmaceuticals company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.